EP1984006B1 - Konditionierte blutzusammensetzung und verfahren zu deren herstellung - Google Patents
Konditionierte blutzusammensetzung und verfahren zu deren herstellung Download PDFInfo
- Publication number
- EP1984006B1 EP1984006B1 EP07711428A EP07711428A EP1984006B1 EP 1984006 B1 EP1984006 B1 EP 1984006B1 EP 07711428 A EP07711428 A EP 07711428A EP 07711428 A EP07711428 A EP 07711428A EP 1984006 B1 EP1984006 B1 EP 1984006B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- blood
- blood composition
- composition according
- vessel
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 195
- 239000008280 blood Substances 0.000 title claims abstract description 195
- 239000000203 mixture Substances 0.000 title claims abstract description 139
- 230000001143 conditioned effect Effects 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 title claims abstract description 35
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 241001465754 Metazoa Species 0.000 claims abstract description 26
- 210000002966 serum Anatomy 0.000 claims description 35
- 238000011282 treatment Methods 0.000 claims description 25
- 238000011534 incubation Methods 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 102000004889 Interleukin-6 Human genes 0.000 claims description 20
- 108090001005 Interleukin-6 Proteins 0.000 claims description 20
- 229940100601 interleukin-6 Drugs 0.000 claims description 20
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 15
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 15
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims description 14
- 102000000589 Interleukin-1 Human genes 0.000 claims description 14
- 108010002352 Interleukin-1 Proteins 0.000 claims description 14
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims description 14
- 102000004388 Interleukin-4 Human genes 0.000 claims description 13
- 108090000978 Interleukin-4 Proteins 0.000 claims description 13
- 229940028885 interleukin-4 Drugs 0.000 claims description 13
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 12
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 12
- 102000003814 Interleukin-10 Human genes 0.000 claims description 12
- 108090000174 Interleukin-10 Proteins 0.000 claims description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 12
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 12
- 229940076144 interleukin-10 Drugs 0.000 claims description 12
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 12
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 11
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 10
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 10
- 102000014429 Insulin-like growth factor Human genes 0.000 claims description 10
- 102000003816 Interleukin-13 Human genes 0.000 claims description 10
- 108090000176 Interleukin-13 Proteins 0.000 claims description 10
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 10
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 10
- 201000009273 Endometriosis Diseases 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 239000011521 glass Substances 0.000 claims description 8
- 230000007794 irritation Effects 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- 241000283086 Equidae Species 0.000 claims description 7
- 208000029549 Muscle injury Diseases 0.000 claims description 7
- QXJJQWWVWRCVQT-UHFFFAOYSA-K calcium;sodium;phosphate Chemical compound [Na+].[Ca+2].[O-]P([O-])([O-])=O QXJJQWWVWRCVQT-UHFFFAOYSA-K 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 206010052428 Wound Diseases 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 6
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 6
- 239000004800 polyvinyl chloride Substances 0.000 claims description 6
- 206010015943 Eye inflammation Diseases 0.000 claims description 5
- 239000004743 Polypropylene Substances 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- -1 polyethylene Polymers 0.000 claims description 5
- 206010028289 Muscle atrophy Diseases 0.000 claims description 4
- 208000029578 Muscle disease Diseases 0.000 claims description 4
- 235000013312 flour Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 210000000653 nervous system Anatomy 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 210000001808 exosome Anatomy 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 2
- 206010049565 Muscle fatigue Diseases 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 239000010431 corundum Substances 0.000 claims description 2
- 229910052593 corundum Inorganic materials 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 150000004706 metal oxides Chemical class 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 210000001087 myotubule Anatomy 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 239000010453 quartz Substances 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 4
- 206010061822 Drug intolerance Diseases 0.000 claims 1
- 206010061958 Food Intolerance Diseases 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 230000001195 anabolic effect Effects 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 230000002682 anti-psoriatic effect Effects 0.000 abstract 1
- 230000000767 anti-ulcer Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 description 28
- 108090000695 Cytokines Proteins 0.000 description 28
- 239000012503 blood component Substances 0.000 description 16
- 239000000306 component Substances 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 13
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 210000002435 tendon Anatomy 0.000 description 12
- 238000011049 filling Methods 0.000 description 9
- 241000283073 Equus caballus Species 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 206010012438 Dermatitis atopic Diseases 0.000 description 7
- 201000008937 atopic dermatitis Diseases 0.000 description 7
- 239000005388 borosilicate glass Substances 0.000 description 7
- 239000011324 bead Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 208000030175 lameness Diseases 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000005293 duran Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000008035 Back Pain Diseases 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 241000589902 Leptospira Species 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 208000021945 Tendon injury Diseases 0.000 description 2
- 239000004775 Tyvek Substances 0.000 description 2
- 229920000690 Tyvek Polymers 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002346 musculoskeletal system Anatomy 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241001215120 Leptospirales Species 0.000 description 1
- 206010061223 Ligament injury Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- JZULKTSSLJNBQJ-UHFFFAOYSA-N chromium;sulfuric acid Chemical compound [Cr].OS(O)(=O)=O JZULKTSSLJNBQJ-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- POFWRMVFWIJXHP-UHFFFAOYSA-N n-benzyl-9-(oxan-2-yl)purin-6-amine Chemical compound C=1C=CC=CC=1CNC(C=1N=C2)=NC=NC=1N2C1CCCCO1 POFWRMVFWIJXHP-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Definitions
- the present invention relates to methods of preparing conditioned blood compositions containing induced factors or cytokines, and to conditioned blood compositions and their use for treating or preventing a condition of the human or animal body.
- blood components especially proteins, factors or cytokines such as erythropoietin, insulin or interferon, which are contained in the blood or blood serum, are therapeutically or prophylactically effective.
- cytokines such as erythropoietin, insulin or interferon
- IL-1Ra interleukin-1 receptor antagonist
- blood components are partly produced by the blood tissue itself or are secreted from the blood cells into the plasma phase of the blood.
- the production or release of certain blood components can be increased, for example, by incubation of whole blood taken from an animal or human body. After incubation, there is often a higher concentration of certain factors in the incubated blood. These blood components can then optionally be isolated. Also, the blood containing the induced factors may be cellular Components are released and (so-called) induced so-called induced blood serum in the animal or human body.
- induction The process of increasing the production or release of blood components such as factors or cytokines is referred to as "induction".
- a known method of inducing blood components in whole blood is essentially to take whole blood from an animal or human body and then to incubate it in a modified disposable syringe in which special chromium-sulfuric acid-treated glass beads are incubated for a certain time under cultivation conditions ( Meijer et al. Inflamm. res. 52 (2003): 1-4 ). Subsequently, the cellular components are separated to obtain a conditioned blood serum composition wherein some factors or cytokines are induced.
- a serum is obtained from human venous whole blood in which the proportion of the anti-inflammatory cytokines interleukin-1 receptor antagonist (IL-1Ra), interleukin-4 (IL-4) and interleukin-10 (IL-10) over freshly withdrawn whole blood is increased.
- the incubation period of the whole blood is 24 hours, the incubation temperature about 37 ° C.
- Blood serum compositions prepared in this way are used for the treatment of various inflammatory diseases and autoimmune diseases, for example rheumatoid arthritis. It can be seen, for example, that rheumatoid arthritis can be alleviated or cured by local and / or systemic administration of such conditioned blood serum compositions. However, the effectiveness of the therapy is in need of improvement.
- muscle injuries which can be treated, at least in the animal model by local or systemic administration of genetically engineered cytokines such as IL-1 Ra and the like.
- the blood serum compositions which can be prepared in a known manner show no or only insufficient effects.
- muscle injuries are common, especially in the field of sports medicine; they account for up to 30% of sports-acquired illnesses or injuries. More than 90% of these muscle injuries are caused either by bruising or by extreme stretching of the muscle. These injuries lead to severe pain and consequently to the inability to continue exercising or to continue practicing the sport in the short or long term.
- the prior art is therefore in need of improvement.
- a serious disease in the horse is the chronic or periodic eye inflammation (equine recurrent uveitis, ERU).
- ERU chronic recurrent uveitis
- this chronic inflammation assumes that the allergy to so-called leptospira and an acute or chronic leptospiral infection is of importance the onset of chronic eye inflammation has.
- a degree of contamination of up to 80% prevails for these parasitic organisms.
- various clinical pictures manifest themselves, including chronic eye inflammation. Decisive for the pathogenesis seems to be whether the immune system of the animal tolerates the leptospira as parasitic organisms or not.
- lameness can occur from massive inflammation or irritation of the tendon sheath. Another cause of lameness may also be degenerative changes within the tendon tissue, called “core lesions”. These also cause massive inflammatory reactions.
- the symptoms of inflammation and lameness are usually treated with glucocorticoids (cortisone), cell macerates (ACell®), platelet concentrates (Osteokin®, Magellan® etc.), or cell preparations from bone marrow or adipose tissue ("stem cells”).
- inflammations or irritations of the nervous system usually of unknown origin, frequently occur in the population.
- back pain is a frequently occurring symptomatology.
- analgesics or glucocorticoids such as triamcinolone
- Endometriosis is a disease in which cells or tissue from the uterine mucosa settle in the abdominal cavity and lead there to mostly benign tumors. This tumor is usually sensitive to hormones and produces, depending on the hormone situation, severe pain. Surgical resection or hormone treatment may be helpful against the symptoms associated with this condition Remedy. However, relapses and recurrences occur regularly. Tumors can chronize to the point that other organs grow together and severe chronic pain develops. The symptoms can often be made bearable only with strong fluxes. About 10% of all women between puberty and menopause contract endometriosis and develop more or less severe symptoms. An extreme manifestation of this disease can lead to infertility.
- At least one modified vessel is used in the incubation of the blood, which is characterized in that it has an inner surface per 1 ml of incubated blood of at least 200 mm 2 / ml or more, especially 224 mm 2 / ml or more or 283 mm 2 / ml or more.
- the vessel has an internal surface area of about 200 to about 750 mm 2 / ml, more preferably about 250 to about 650 mm 2 / ml.
- the vessel has a filling volume of 5 ml or more, 10 ml or more, 50 ml or more, 60 ml or more or 100 ml or more.
- the inner surface of the modified vessel according to the invention at least about 6,600 mm 2 (66 cm 2 ), preferably about 10,000 mm 2 to about 37,500 mm 2 (100 bis 375 cm 2 ).
- the inner surface of the modified vessel according to the invention at least about 2300 mm 2 (23 cm 2 ), preferably about 2,500 mm 2 to about 7,500 mm 2 (25 bis 75 cm 2 ).
- Inner surface of the vessel is understood to mean that surface in the interior of the vessel which, during incubation, is in contact with the blood composition to be conditioned, that is to say is substantially wetted by it.
- the invention contemplates that blood taken from a human or animal body should be incubated in a special modified vessel having a surface area index of the internal surface of 200 mm 2 / ml or more.
- the inventors have surprisingly found that the method according to the invention makes it possible to obtain a conditioned blood composition in the modified vessel which contains a high proportion of certain induced factors and in which, for example, the factor IL-6 is present in a high concentration even after a comparatively short time.
- the procedure according to the invention leads to a blood composition which has prophylactic and therapeutically high activity.
- inflammatory joint diseases, eye irritation in horses, tendon injuries, nerve injuries, endometriosis, atopic dermatitis and muscle injuries can be effectively treated by the obtained according to the invention received conditioned blood composition as blood serum composition in the diseased organism or in or on the diseased organ.
- a conditioned blood composition can be obtained from freshly drawn whole blood of human donors, wherein IL-6 is present in a freshly withdrawn portion of more than 2000 pg / ml.
- the level of IL-6 in unconditioned whole blood is from about 0.5 to about 15 pg / ml.
- an approximately 200-fold to about 4000-fold increase in the content of IL-6 achieved.
- IL-6 further therapeutically and prophylactically active components such as factors or cytokines are obtained in a high proportion in the conditioned blood composition.
- these also surprisingly include factors such as interleukin-13 (IL-13), interleukin-1 (IL-1), above all IL-1 ⁇ , tumor necrosis factor (TNF ), Insulin-like growth factor (IGF), transforming growth factor (TGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and hepatocyte growth factor (HGF).
- TNF tumor necrosis factor
- IGF Insulin-like growth factor
- TGF transforming growth factor
- PDGF platelet-derived growth factor
- FGF fibroblast growth factor
- HGF hepatocyte growth factor
- the abovementioned active ingredients within the blood composition may also be present in the form of vesicles, microvesicles or exosomes.
- Vesicles or microvesicles are understood as subcellular components which, among other things, can be constricted by the membrane surface of immune cells.
- Exosomes are subcellular components that represent vesicle-like structures in the nanometer range and are formed by invaginations of so-called "multivesicular bodies" and secretion by immune cells.
- a "blood composition” is understood here to mean a composition of blood, in particular consisting of blood plasma, serum and blood cells, which contains at least one component selected from proteins such as factors and cytokines.
- a blood composition is also understood to mean a blood serum composition.
- a blood serum composition differs from a blood composition mainly in that the blood serum composition contains no cellular components (more).
- a conditioned blood serum composition is obtained from a conditioned blood composition obtainable according to the invention by, for example, separating the cellular constituents from the blood composition by centrifugation, filtration or other suitable means to provide a cell-free solution of blood plasma and serum components containing at least the induced factors and cytokines. is obtained.
- the cellular constituents are completely or substantially completely separated from the resulting conditioned blood composition so that a conditioned blood serum composition is obtained.
- the conditioned blood serum can be used in the same way as the blood composition obtainable according to the invention and usually gives the same technical advantages according to the invention.
- the skilled artisan will use the conditioned blood serum composition or the conditioned whole blood composition depending on the field of application and convenience. Preferably, he will use the conditioned blood serum composition.
- the incubation of the blood in the at least one modified vessel is carried out until the induction of the factors or cytokines has progressed sufficiently far.
- the induced factors or cytokines are produced and secreted by the blood tissue substantially from the time of commencement of the incubation so that an effective amount of the induced factors or cytokines accumulates in the conditioned blood composition.
- the presence of IL-6 in the blood composition indicates successful and sufficiently advanced induction.
- the proportion of IL-6 is at least 30 pg / ml.
- incubation is carried out in the modified vessel until at least 30 pg / ml IL-6 is present in the blood composition.
- incubated is at least 200 pg / ml, preferably 500 pg / ml, more preferably 1000 pg / ml are present in the blood composition.
- incubated for a period of 36 hours or less. In another embodiment, incubation is carried out for a period of 9 hours or less. In a further variant incubation is carried out for a period of 2 or more and up to 36 or less, preferably up to 9 or less hours.
- the incubation of the blood takes place under low oxygen partial pressure (pO 2 ).
- the oxygen partial pressure during incubation is less than 5 kPa, preferably less than 3 kPa.
- the incubation of the blood takes place in the modified vessel with oxygen termination.
- the modified vessel has in its interior special structures with a large surface, so that the (outer) geometry of the vessel primarily resulting inner surface is increased by the special structures.
- the surface enlargement by the particular structures is preferably from 10% to about 200%, in a variant from 10% to 100%.
- These include preferably structures with a high surface volume ratio, such as spheres and fibers, but also other particles, such as flour and granules, or combinations of such structures.
- the surface of these structures is preferably smooth. Alternatively, in some cases, rough surface structures may be used.
- the person skilled in the art will choose the number and shape of the internal structures according to the field of application and expediency. It is understood that the shape and number of the internal structures to be added is chosen so that the sum of the surface of the added internal structures and the inner surface of the vessel to be modified is coordinated so that the provided according to the invention surfaces / volume Ratio (surface index) is obtained.
- the modified vessel has a non-pyrogenic inner surface.
- the modified vessel is constructed of pyrogen-free material.
- particulate internal structures such as spheres, fibers, flour, granules or mixtures thereof are used, they contain or preferably consist of materials selected from metals, metal oxides or plastics and mixtures thereof.
- preferred examples include glass, corundum, quartz, polystyrene, polyvinyl chloride, polyethylene and polypropylene, and mixtures thereof.
- Particularly preferred is borosilicate glass. These materials are preferably pyrogen-free.
- the at least one modified vessel preferably contains glass spheres in its interior, particularly preferably pyrogen-free borosilicate glass, the glass spheres having a (mean) diameter of 0.5 to 5 mm, preferably 1.5 mm, 2.5 mm or 3.5 mm, exhibit.
- the glass spheres in a number of about 10 to 500 are particularly preferably added to the vessel to be modified.
- a vessel is provided for receiving about 50 ml of blood, preferably about 30 to 300 balls, especially about 50 to 250 balls are filled, which have a diameter of preferably 3.5 mm.
- a blood collection or blood storage vessel such as a syringe, blood tube or blood bag, which is preferably known from transfusion medicine, is used, which is modified by adding a certain proportion of such internal structures, so that a modified vessel having an enlarged inner surface is obtained becomes.
- the invention accordingly provides for the preparation of a conditioned blood composition the use of at least one modified large internal surface vessel having a surface index according to the invention which contains internal structures selected from spheres, fibers, flour, granules, particles or combinations thereof.
- a vessel is provided whose inner vessel walls have protuberances, cavities and / or protrusions, so that the surface volume ratio (surface index) provided according to the invention is achieved.
- the modified vessel has elastic vessel walls, which preferably allow an air-free removal of blood from the animal or human body when the substantially still evacuated modified vessel expands only with the influx of blood, so that no unwanted air space in the vessel can arise. It should be understood that the number and surface area of internal structures provided in the modified vessel to increase its internal surface is not oriented to the maximum capacity of the elastic vessel, but rather to the volume of the blood composition to be incubated.
- such an elastic vessel is selected from blood bags provided in transfusion medicine, which are preferably single, double, triple or multiple bag systems. While a single bag system is characterized in that usually has at least one opening for filling or emptying, double, triple and multiple bags represent arrangements of several mutually communicating bag, which are preferably in contact with each other by means of hose connection. Preferably, such bags are in simple way of two welded together elastic films.
- the at least one modified vessel used according to the invention is a blood bag or blood bag system which has been modified by filling a number and type of particles, preferably glass beads, chosen according to the invention.
- the vessel is a bag system as used as a two-chamber blood bag system for centrifuges for separating blood components in freshly drawn blood.
- the vessel according to the invention is modified, preferably by filling with glass beads, the inventive method for producing a conditioned blood composition can be carried out therein become.
- the blood components in the blood bag system are separated to obtain a conditioned blood serum composition free of "solid" blood components.
- a preferred dual-chamber blood bag system comprises at least one primary vessel and at least one secondary vessel which form a communicating vasculature.
- Primary vessel and secondary vessel are connected via at least one, in particular closable, connection.
- a "primary vessel” is preferably understood to mean a vessel, that is to say vessels, in which the blood composition to be conditioned and subsequently optionally incorporated into its individual components is incubated and, if appropriate, subjected to a first fractionation becomes.
- primary vessel, secondary vessel and transfer are expediently fixed to a carrier plate.
- the transfer is closed by at least one interruption which can be designed as a valve, cock and / or plug, lockable.
- a “secondary vessel” is understood to mean a vessel, that is to say a vessel, in which the liquid or suspension, which is optionally completely or partially separated into its individual components in the primary vessel, is completely or partially introduced and subjected to a second fractionation.
- Each of these vessels is preferably provided with in each case at least one, in particular closable, supply and / or supply line, in particular for the supply, that is to say introduction or re-application, of blood components and / or removal, ie removal, of blood components.
- the additional internal structures according to the invention, such as glass beads, are preferably provided in the primary vessel or filled therein.
- the bag or blood bag system is used to separate the solid blood components from the conditioned blood serum composition by centrifugation into a centrifuge cup.
- a centrifuge cup This is preferably designed so that the preferably designed as an elastic bag vessel is stretched during centrifugation so that the vessel walls partially and / or completely come to rest on the inner wall of the centrifuge cup. Preference is given to the use of a sterile cup. In this way, the strain load on the vessel walls and the cells contained therein is particularly advantageously reduced during the centrifugation.
- the preferred use of a centrifuge bowl also allows the use of mechanically lighter, thinner and less stable wall material for the preferred elastic bag.
- the incubated blood composition is an allogeneic blood composition, preferably a blood composition taken in the form of whole blood from a human or animal donor and administered to the human donor after performing the method of the invention as a conditioned blood composition, preferably as a conditioned blood serum composition.
- the blood composition is autologous, that is, donor organism and recipient organism are identical.
- all the benefits of the autologous donation can come to fruition.
- the skilled person will choose the type and identity of the dispenser depending on the application and the purpose. In general, the known criteria and benefits relevant to the selection of an autologous donation may be considered.
- the blood composition is xenogeneic. That is, it is taken from a foreign organism.
- the unconditioned blood composition in the form of whole blood is preferably taken from an animal donor organism, for example a pig, and after carrying out the method according to the invention, the conditioned blood composition is administered to the individual to be treated, which belongs to another species, for example horse, human or athlete.
- a further aspect of the invention is the provision of a conditioned blood composition, which by the inventive Method can be produced or is preferably prepared.
- This can be used according to the invention for the treatment, alleviation, cure or prevention of a disease of the human or animal body.
- this blood composition contains the factors induced in carrying out the method according to the invention, at least 30, preferably more than 200, 1000, 5000, 10 000 pg / ml, preferably from 30 to 20 000 pg / ml interleukin-6.
- the conditioned blood composition preparable by means of the method according to the invention has further induced factors in addition to interleukin-6 as one of the induced factors. It has surprisingly been shown that the composition of the induced factors obtainable in accordance with the invention in a "cocktail" has the advantages according to the invention Has effects.
- a conditioned blood composition which, in addition to interleukin-6 (IL-6), has at least one further component which is selected from: interleukin-1 receptor antagonist (IL-1Ra), interleukin-4 (IL-4), interleukin 13 (IL-13), Interleukin-1 (IL-1), Interleukin-10 (IL-1), Tumor necrosis factor (TNF), Insulin-like growth factor (IGF), Transforming growth factor (TGF), Platelet -derived growth factor (PDGF), fibroblast growth factor (FGF) and hepatocyte growth factor (HGF).
- IL-1Ra interleukin-1 receptor antagonist
- IL-4 interleukin-4
- IL-13 interleukin 13
- IL-1 Interleukin-1
- IL-1 Interleukin-10
- TGF Tumor necrosis factor
- IGF Insulin-like growth factor
- TGF Transforming growth factor
- PDGF Platelet -derived growth factor
- FGF fibroblast growth factor
- HGF hepatocyte growth factor
- the conditioned blood composition contains interleukin-1 receptor antagonist (IL-1Ra) in an amount of 30 to 50,000 pg / ml.
- the conditioned blood composition contains interleukin-4 (IL-4) in a proportion of 2 to 100 pg / ml.
- the conditioned blood composition contains interleukin-13 (IL-13) in a proportion of 2 to 100 pg / ml.
- the conditioned blood composition contains interleukin-1 (IL-1) in a proportion of 5 to 1,000 pg / l.
- the conditioned blood composition contains interleukin-10 (IL-10) at a level of 5 to 1,000 pg / l.
- the conditioned blood composition contains tumor necrosis factor (TNF) in a proportion of 5 to 1,000 pg / ml.
- the conditioned blood composition contains insulin-like growth factor (IGF) in a proportion of 100 to 15,000 pg / ml.
- the conditioned blood composition contains transforming growth factor (TGF) in a proportion of 10 to 20,000 pg / ml.
- the conditioned blood composition contains Platelet-derived growth factor (PDGF) in a proportion of 100 to 10,000 pg / ml.
- the conditioned blood composition contains fibroblast growth factor (FGF) in a proportion of 50 to 10,000 pg / ml.
- the conditioned blood composition contains hepatocyte growth factor (HGF) in a proportion of 50 to 10,000 pg / ml.
- the cocktail of induced factors and cytokines present in the conditioned blood composition obtainable according to the invention has a particularly effective prophylactic and therapeutic action.
- the conditioned blood composition or the conditioned blood serum composition obtainable therefrom it is used particularly effectively in a number of diseases or ailments of the human or animal body which are treated, cured or alleviated thereby or which prevents these diseases and ailments.
- the conditioned blood composition or blood serum composition obtainable in accordance with the invention is used for muscle diseases, disorders of the musculoskeletal system as well as inflammations and irritations of the nervous system, especially diseases of the tendon, such as tendon injuries, tendonitis, ligament injuries, tendon degeneration and ligament degeneration, as well as for rapid healing, relief or for the prevention of allergies, intolerances to food or medicine, diseases involving the immune system, especially.
- Musculoskeletal disorders include muscular disorders caused by muscle injury during muscle surgery, muscle fiber tears associated with muscle degeneration, muscle damage, muscle atrophy, muscle breakage, muscular dystrophy, muscle fatigue or muscle soreness.
- the present invention therefore relates to the use of the inventive blood composition of the conditioned blood serum composition obtainable therefrom for the treatment or prevention of a disease of the human or animal body.
- the suffering of the human or animal body which may be favorably treated, alleviated or cured or prevented, is selected from diseases of the rheumatoid Musculoskeletal disorders, diseases of the musculoskeletal system and diseases related to the immune system and diseases that cause acute or chronic pain.
- the person skilled in the art will choose the respectively appropriate mode of administration for the administration of the conditioned blood composition according to the invention.
- the conditioned blood or blood serum composition is injected or infused into the body and / or the affected organ such as the joint, muscle, tendon, skin or nerve, preferably intravenously, intraarterially, subcutaneously, intradermally, subconjunctively, topically, intrathecally, perispinally, in and / or central nerves, in and / or peripheral nerves, intra-articularly and / or intramuscularly.
- the conditioned blood composition according to the invention is therefore used for the manufacture of a medicament for the treatment or prevention of a condition of the human or animal body.
- a use of the blood composition according to the invention is also provided as a non-therapeutic cosmetic, as a so-called "anti-aging” agent. It has been shown that by systematic and / or topical administration physical side effects of age, especially the aforementioned symptoms, alleviated the cured but also the external appearance: skin, hair, nails can be improved.
- the invention uses the blood composition according to the invention for the production of cosmetics.
- the present invention also relates to a method for the treatment or prevention of a previously characterized human or animal body condition which comprises at least the following step: administering the conditioned blood composition according to the invention to the human or animal body in a therapeutically or prophylactically effective dose.
- the specialist selects the dose and the type of administration according to the field of application and expediency.
- FIG. 1 shows a schematic representation of a preferred embodiment of the device according to the invention, consisting of a trained as an elastic bag vessel (10) having a preferably semicircular lower portion (14) and a preferably tapered upper portion (15) with at least one inlet and / or outlet (11), which opens into the funnel-shaped upper portion (15) of the vessel.
- a lip valve (13) At its lower end, which opens into the lumen of the vessel 10, a lip valve (13), that is flutter valve, is preferably provided.
- Example 1 Kit for obtaining conditioned blood composition from whole blood
- All components are disposable, packaged and gamma-sterilized and provided with sterile outer packaging as a whole.
- Tables 1 and 2 list the materials of the components used. ⁇ u> Table 1: ⁇ / u> component Material, supplier Pouch (10) Bag film: PVC compound 3222 (Solvay Draka) internal structures 200 borosilicate glass spheres, 3.5 mm diameter (Duran®) component Material, supplier inventive device (see Table 1) Butterfly cannula 1.1 ⁇ 19 Cap: PE mm LL adapter: ABS transparent Wing Connection head: PVC Tube: PVC 60 Sh A cannula: ISO 638/13 Conduit: PE Cannula 1.1 ⁇ 40 mm Connection head: PP Protective cap: PP cannula: Stainless steel according to DIN EN ISO 9626 60 ml syringe Cylinder: PP Rod: PP Plunger stopper: natural rubber 10 ml syringe (12 cc) Cylinder: PP Rod: PP Plunger stopper: PP Perfusor line 1.5 m, LL male: ABS KR 2802 1.0 x 2.7
- Example 2 Obtaining a Conditioned Blood Serum Composition from Whole Blood
- the blood is taken with a 60 ml Luerlock syringe.
- the syringe is slowly filled to the 60 ml mark with whole blood. Pay attention to bubble-free filling so that there are actually exactly 60 ml in the syringe.
- the contents of the syringe are slowly and completely filled via the inlet / outlet (11) into the vessel (10) designed as an elastic bag.
- the vessel (10) designed as an elastic bag.
- the syringe is unscrewed after filling and the port (12) of the bag is closed again with a new cap.
- the vessel (10) is preferably suspended at about 37 ° C for 9 to 36 hours.
- the blood taken in the vessel is incubated with the balls enlarging the inner surface.
- the increased inner surface is about 350 mm 2 per 1 ml of incubated blood.
- the vessel (10) is used in a centrifuge cup. After checking for correct weight balance, centrifugation at about 2500 rpm for carried out for about 3 minutes. After the centrifugation, in which a separation of the cellular blood components of the liquid takes place, the centrifuge cup is carefully removed together with the vessel (10).
- Centrifugation has accumulated blood cells, mainly erythrocytes (EC), in the lower part of the vessel (10).
- the centrifugation separates serum from the blood clot.
- the serum is transferred to the second bag and then optionally centrifuged a second time.
- the conditioned serum composition is withdrawn via the withdrawal connection of the supply / discharge line (11).
- the filled syringe is then unscrewed.
- Example 3 Analysis of conditioned blood serum composition
- a commercially available blood bag (OSTEOKIN, Orthogen, Dusseldorf), which is essentially described in Examples 1 and 2, was filled with 210 balls of borosilicate glass (Duran®) with a diameter of 3.5 mm.
- Duran® borosilicate glass
- the inner surface of the modified vessel is about 18,125 mm 2 in total.
- the surface / volume ratio (surface index) of the modified vessel is about 360 mm 2 / ml.
- a further batch B the same blood bag system was used as in batch A, in which no additional internal structures were filled.
- the unfilled blood bag system has an inner Surface of about 10,000 mm 2 on. For 50 ml of blood this corresponds to a surface index of about 200 mm 2 / ml.
- a further batch C the same blood bag system was used as in batch A and filled with 780 glass balls with a diameter of 3.5 mm. The inner surface is then about 40,000 mm 2 in total. With a filling quantity of 50 ml of blood, a surface index of about 800 mm 2 / ml results.
- another blood collection system having a substantially cylindrical shape was filled with 36 glass beads of 1.5 mm diameter.
- the inner surface is then about 4050 mm 2 in total.
- At a capacity of 10 ml of blood results in a surface index of about 405 mm 2 / ml.
- a blood collection system having a substantially cylindrical shape was filled with 62 3.5 mm diameter glass spheres.
- the inner surface is then about 6200 mm 2 in total.
- At a filling level of 10 ml of blood results in a surface index of about 620 mm 2 / ml.
- Venous whole blood was freshly withdrawn from each of the experimental batches and filled into the tubes of the batches A, B and C in each case.
- the blood components IL-1Ra, IL-6, TNFa and IL-1 ⁇ in the blood compositions were quantitated.
- Example 4 Cytokine profile of the conditioned blood composition
- cytokines FGF, IL-4, IL-10, IL-1 ⁇ , TNF, IL-6, IL-1Ra and TGF ⁇ was determined.
- Example 5 Treatment of atopic dermatitis
- the conditioned blood composition prepared according to the invention was administered to patients in the form of injections, also as intraarticular injections.
- 2 ml of the conditioned blood composition are injected over a period of 3 weeks at intervals of 2 to 3 days.
- An improvement in the symptoms of atopic dermatitis was found within 3 days.
- a renewed flare up Disease at approximately 2.5 months was also successfully treated with 3 injections.
- Example 6 Treatment of inflammation or irritation of the nervous system
- the analgesic effect of the blood composition conditioned according to the invention surprisingly goes far beyond the effect of normal analgesics
- Example 8 Chronic ocular inflammation in the horse
- the conditioned blood composition prepared according to the invention was injected into the eye (subconjunctival) or dropped into the eye (topical) to 6 horses, of which 3 horses each were treated in two different veterinary practices. Within the follow-up period of up to 10 months, no relapse was observed in any of the treated cases.
- Example 9 Regeneration and pain improvement of irritation of the tendons in the horse
- the conditioned blood composition were horses with lameness due to massive inflammation or irritation of the tendon sheath associated with effusion in the tendon sheath, with injections of 3 ml each of the conditioned blood serum of the invention Tendon sheath treated.
- the effusion was first punctured in a first step in order to reduce the pressure on the tissue and to remove proinflammatory substances. After the first injection, both lameness and the amount of effusion seen in the second week decreased significantly within one week. After 4 weeks, one week after injection of the third and last dose into the tendon sheath, almost complete remission of both lameness and effusion was observed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09013177A EP2156841A1 (de) | 2006-02-03 | 2007-02-02 | Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung |
PL07711428T PL1984006T3 (pl) | 2006-02-03 | 2007-02-02 | Kondycjonowana kompozycja krwi i sposób jej wytwarzania |
SI200730130T SI1984006T1 (sl) | 2006-02-03 | 2007-02-02 | Kondicionirana krvna sestavina in postopek za njeno pripravo |
CY20101100046T CY1109735T1 (el) | 2006-02-03 | 2010-01-15 | Επεξεργασμενη συνθεση αιματος και μεθοδος για την παραγωγη της |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006005016A DE102006005016A1 (de) | 2006-02-03 | 2006-02-03 | Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung |
PCT/EP2007/000903 WO2007090569A1 (de) | 2006-02-03 | 2007-02-02 | Konditionierte blutzusammensetzung und verfahren zu deren herstellung |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1984006A1 EP1984006A1 (de) | 2008-10-29 |
EP1984006B1 true EP1984006B1 (de) | 2009-10-21 |
Family
ID=37965046
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09013177A Withdrawn EP2156841A1 (de) | 2006-02-03 | 2007-02-02 | Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung |
EP07711428A Revoked EP1984006B1 (de) | 2006-02-03 | 2007-02-02 | Konditionierte blutzusammensetzung und verfahren zu deren herstellung |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09013177A Withdrawn EP2156841A1 (de) | 2006-02-03 | 2007-02-02 | Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung |
Country Status (24)
Country | Link |
---|---|
US (1) | US20090047242A1 (ja) |
EP (2) | EP2156841A1 (ja) |
JP (1) | JP2009525297A (ja) |
KR (1) | KR20080100425A (ja) |
CN (1) | CN101378768A (ja) |
AT (1) | ATE446100T1 (ja) |
AU (1) | AU2007213996A1 (ja) |
BR (1) | BRPI0707360A2 (ja) |
CA (1) | CA2640002A1 (ja) |
CY (1) | CY1109735T1 (ja) |
DE (2) | DE102006005016A1 (ja) |
DK (1) | DK1984006T3 (ja) |
EA (1) | EA014435B1 (ja) |
ES (1) | ES2335446T3 (ja) |
HK (1) | HK1125835A1 (ja) |
HR (1) | HRP20090684T1 (ja) |
MX (1) | MX2008009807A (ja) |
PL (1) | PL1984006T3 (ja) |
PT (1) | PT1984006E (ja) |
RS (1) | RS51247B (ja) |
SI (1) | SI1984006T1 (ja) |
UA (1) | UA90048C2 (ja) |
WO (1) | WO2007090569A1 (ja) |
ZA (1) | ZA200805975B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102012019088A1 (de) * | 2012-09-28 | 2014-04-03 | Orthogen Ag | Antibakterielle Arzneimittelpräparate |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
US20060278588A1 (en) | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
US8034014B2 (en) | 2007-03-06 | 2011-10-11 | Biomet Biologics, Llc | Angiogenesis initation and growth |
US20080269762A1 (en) * | 2007-04-25 | 2008-10-30 | Biomet Manufacturing Corp. | Method and device for repair of cartilage defects |
US8753690B2 (en) | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
EP2620139B1 (en) * | 2008-02-27 | 2016-07-20 | Biomet Biologics, LLC | Interleukin-1 receptor antagonist rich solutions |
DE102008028684A1 (de) * | 2008-06-17 | 2009-12-24 | Kopetzky, Robert, Dr. | Blutbeutel |
US8460227B2 (en) | 2008-11-17 | 2013-06-11 | Arthrex, Inc. | Cytokine concentration system |
EP2416789B1 (en) | 2009-04-07 | 2017-06-21 | Velin-Pharma A/S | Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system |
CA2772084C (en) | 2009-08-27 | 2016-10-18 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
DK2475372T4 (da) | 2009-09-10 | 2020-11-30 | Velin Pharma As | Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse |
DE202009017772U1 (de) | 2009-12-10 | 2011-04-21 | Orthogen Ag | Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid |
AU2011296356B2 (en) | 2010-09-03 | 2015-07-09 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
DE102010042356A1 (de) * | 2010-10-12 | 2012-04-12 | Henke-Sass, Wolf Gmbh | Behälter für die Herstellung einer konditionierten Blutzusammensetzung |
US9011846B2 (en) | 2011-05-02 | 2015-04-21 | Biomet Biologics, Llc | Thrombin isolated from blood and blood fractions |
US9205110B2 (en) | 2012-07-18 | 2015-12-08 | Arthrex, Inc. | Enhanced autologous growth factor production and delivery system |
HUE056391T2 (hu) | 2013-02-12 | 2022-02-28 | Lacerta Tech Inc | Vérlemezkedús fibrin szérumfrakciója |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
EP2829278A1 (de) * | 2013-07-23 | 2015-01-28 | Scientific BioTech GmbH | Serum zur Behnandlung von Krankheiten |
EP3074507B1 (en) | 2013-11-26 | 2022-01-05 | Biomet Biologics, LLC | Methods of mediating macrophage phenotypes |
WO2015085348A1 (en) * | 2013-12-09 | 2015-06-18 | Cytokine Medical Australia Pty Ltd | Apparatus for producing therapeutically active proteins in blood and uses thereof |
US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
CR20190139A (es) * | 2016-08-17 | 2019-06-03 | Orthogen Ag | Preparación farmacéutica anti envejecimiento |
EP3613424A1 (en) | 2018-08-23 | 2020-02-26 | Orthogen AG | Novel methods for the production of pharmaceutical agents |
DE102021124752A1 (de) | 2021-09-24 | 2023-03-30 | Ad Lentus GmbH | Autologes Therapeutikum und Verfahren zur Herstellung desselben |
CN114146096B (zh) * | 2021-11-25 | 2024-04-02 | 成都清科生物科技有限公司 | 一种富含细胞因子的条件血清的制备方法及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4244437A1 (de) * | 1992-12-29 | 1994-07-28 | Horst Dr Med Kief | Verfahren zur Gewinnung körpereigener Zytokine |
DE19903876B4 (de) * | 1999-02-01 | 2006-09-28 | Orthogen Gentechnologie Gmbh | Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten |
US20020081324A1 (en) * | 2002-01-22 | 2002-06-27 | Twine Rebecca Wright | Method of treating aging skin and wrinkles using a combination of growth factors that is commercially prepared or derived from one's own blood |
-
2006
- 2006-02-03 DE DE102006005016A patent/DE102006005016A1/de not_active Withdrawn
-
2007
- 2007-02-02 ES ES07711428T patent/ES2335446T3/es active Active
- 2007-02-02 CA CA002640002A patent/CA2640002A1/en not_active Abandoned
- 2007-02-02 PL PL07711428T patent/PL1984006T3/pl unknown
- 2007-02-02 BR BRPI0707360-7A patent/BRPI0707360A2/pt not_active IP Right Cessation
- 2007-02-02 AU AU2007213996A patent/AU2007213996A1/en not_active Abandoned
- 2007-02-02 CN CNA2007800044614A patent/CN101378768A/zh active Pending
- 2007-02-02 PT PT07711428T patent/PT1984006E/pt unknown
- 2007-02-02 AT AT07711428T patent/ATE446100T1/de active
- 2007-02-02 ZA ZA200805975A patent/ZA200805975B/xx unknown
- 2007-02-02 KR KR1020087018622A patent/KR20080100425A/ko not_active Application Discontinuation
- 2007-02-02 MX MX2008009807A patent/MX2008009807A/es not_active Application Discontinuation
- 2007-02-02 WO PCT/EP2007/000903 patent/WO2007090569A1/de active Application Filing
- 2007-02-02 SI SI200730130T patent/SI1984006T1/sl unknown
- 2007-02-02 EP EP09013177A patent/EP2156841A1/de not_active Withdrawn
- 2007-02-02 UA UAA200810851A patent/UA90048C2/ru unknown
- 2007-02-02 JP JP2008552751A patent/JP2009525297A/ja not_active Withdrawn
- 2007-02-02 DE DE502007001793T patent/DE502007001793D1/de active Active
- 2007-02-02 EP EP07711428A patent/EP1984006B1/de not_active Revoked
- 2007-02-02 RS RSP-2010/0012A patent/RS51247B/sr unknown
- 2007-02-02 EA EA200870222A patent/EA014435B1/ru not_active IP Right Cessation
- 2007-02-02 DK DK07711428.8T patent/DK1984006T3/da active
- 2007-02-02 US US12/162,022 patent/US20090047242A1/en not_active Abandoned
-
2009
- 2009-04-28 HK HK09103942.4A patent/HK1125835A1/xx not_active IP Right Cessation
- 2009-12-23 HR HR20090684T patent/HRP20090684T1/hr unknown
-
2010
- 2010-01-15 CY CY20101100046T patent/CY1109735T1/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102012019088A1 (de) * | 2012-09-28 | 2014-04-03 | Orthogen Ag | Antibakterielle Arzneimittelpräparate |
Also Published As
Publication number | Publication date |
---|---|
BRPI0707360A2 (pt) | 2011-05-03 |
DK1984006T3 (da) | 2010-03-01 |
MX2008009807A (es) | 2008-09-26 |
HRP20090684T1 (hr) | 2010-02-28 |
EP1984006A1 (de) | 2008-10-29 |
PT1984006E (pt) | 2010-01-20 |
ATE446100T1 (de) | 2009-11-15 |
US20090047242A1 (en) | 2009-02-19 |
JP2009525297A (ja) | 2009-07-09 |
RS51247B (sr) | 2010-12-31 |
UA90048C2 (ru) | 2010-03-25 |
AU2007213996A1 (en) | 2007-08-16 |
WO2007090569A1 (de) | 2007-08-16 |
DE102006005016A1 (de) | 2007-08-16 |
DE502007001793D1 (de) | 2009-12-03 |
SI1984006T1 (sl) | 2010-02-26 |
CA2640002A1 (en) | 2007-08-16 |
EA200870222A1 (ru) | 2008-12-30 |
PL1984006T3 (pl) | 2010-03-31 |
EP2156841A1 (de) | 2010-02-24 |
ZA200805975B (en) | 2010-08-25 |
HK1125835A1 (en) | 2009-08-21 |
ES2335446T3 (es) | 2010-03-26 |
KR20080100425A (ko) | 2008-11-18 |
WO2007090569A8 (de) | 2008-02-28 |
EA014435B1 (ru) | 2010-12-30 |
CY1109735T1 (el) | 2014-09-10 |
CN101378768A (zh) | 2009-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1984006B1 (de) | Konditionierte blutzusammensetzung und verfahren zu deren herstellung | |
AT411901B (de) | Verfahren zur induktion von therapeutisch wirksamen proteinen durch inkubation einer körperflüssigkeit in einer einen induktor enthaltenden spritze | |
DE69936212T2 (de) | Hydrogelzusammensetzungen mit kontrollierter Freigabe für die Verabreichung von Wachstumsfaktoren | |
DE69434121T2 (de) | Pharmazeutische zusammensetzung zur immunverstärkenden therapie | |
EP2099462A1 (de) | Pharmazeutische zubereitung für die behandlung entzündlicher erkrankungen des urogenitaltraktes | |
WO2011082950A1 (de) | Kombinationspräparate mit exosomen und corticosteroid | |
EP3081220A1 (de) | Verfahren zur herstellung von augentropfen | |
DE10154579A1 (de) | Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen | |
WO2003007988A1 (de) | Flüssige formulierung enthaltend cetuximab und einen polyoxyethylensorbitanfettsäureester | |
DE69129563T2 (de) | Epidermis-Wachstumsfaktor als Arzneimittel zur Wiederherstellung der Neuronen der Substantia nigra in der Behandlung nervenzerstörender Störungen | |
EP2076243B1 (de) | Flüssigformulierung von g-csf | |
WO2012076193A1 (de) | Kombinationspräparate mit exosomen und corticosteroid | |
WO2018206357A1 (de) | Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (20 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis | |
JP2023518085A (ja) | 自家生理学的液体から、強化された抗炎症性/抗異化性作用物質を作製するための方法 | |
EP3415163B1 (de) | Zusammensetzung mit lokalanästhetischer wirkung und deren verwendung | |
DE3421011A1 (de) | Individualmedikament | |
CN112704687A (zh) | 含间充质干细胞的制剂及其在银屑病治疗中的应用 | |
DE60025260T2 (de) | Verwendung des sekretorischen leukozytären Proteasehemmers für Keloide und Narben | |
EP2590659B1 (de) | Gelsolin-angereichertes blut zur therapeutischen verwendung | |
EP0889053B1 (de) | BK-RiV-Präparate zur Behandlung von proliferativen Zellerkrangungen | |
EP2195014B1 (de) | Verwendung von g-csf für die behandlung von schlaganfall | |
EP3400951B1 (de) | Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (4,5 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis | |
EP0899271B1 (de) | Verfahren zur Induktion von therapeutische wirksamen Proteinen | |
DE102007040932A1 (de) | Flüssigformulierung von G-CSF | |
WO1989005343A1 (en) | Process for producing syngeneic cells, and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080903 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
17Q | First examination report despatched |
Effective date: 20090105 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1125835 Country of ref document: HK |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 502007001793 Country of ref document: DE Date of ref document: 20091203 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20090684 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20100113 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20091222 Year of fee payment: 4 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20090684 Country of ref document: HR Payment date: 20100129 Year of fee payment: 4 Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20100400118 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20090684 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2335446 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CZ Payment date: 20100125 Year of fee payment: 4 Ref country code: DK Payment date: 20100222 Year of fee payment: 4 Ref country code: EE Payment date: 20100222 Year of fee payment: 4 Ref country code: ES Payment date: 20100219 Year of fee payment: 4 Ref country code: IE Payment date: 20100219 Year of fee payment: 4 Ref country code: IS Payment date: 20100219 Year of fee payment: 4 Ref country code: LT Payment date: 20100126 Year of fee payment: 4 Ref country code: LU Payment date: 20100219 Year of fee payment: 4 Ref country code: MC Payment date: 20100217 Year of fee payment: 4 Ref country code: PT Payment date: 20100119 Year of fee payment: 4 Ref country code: RO Payment date: 20100125 Year of fee payment: 4 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1125835 Country of ref document: HK |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FI Payment date: 20100219 Year of fee payment: 4 Ref country code: FR Payment date: 20100315 Year of fee payment: 4 Ref country code: LV Payment date: 20100223 Year of fee payment: 4 Ref country code: PL Payment date: 20100125 Year of fee payment: 4 Ref country code: SI Payment date: 20100120 Year of fee payment: 4 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 6838 Country of ref document: SK |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20100224 Year of fee payment: 4 Ref country code: TR Payment date: 20100122 Year of fee payment: 4 |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BG Payment date: 20100223 Year of fee payment: 4 Ref country code: HU Payment date: 20100128 Year of fee payment: 4 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
26 | Opposition filed |
Opponent name: INSPICOS A/S Effective date: 20100719 Opponent name: HENKE-SASS WOLF GMBH Effective date: 20100721 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20100421 Year of fee payment: 4 Ref country code: NL Payment date: 20100218 Year of fee payment: 4 Ref country code: SK Payment date: 20100125 Year of fee payment: 4 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E007944 Country of ref document: HU |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20100129 Year of fee payment: 4 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: PBON Ref document number: P20090684 Country of ref document: HR Effective date: 20110203 |
|
BERE | Be: lapsed |
Owner name: ORTHOGEN A.G. Effective date: 20110228 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20110901 |
|
LTLA | Lt: lapse of european patent or patent extension |
Effective date: 20110202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110228 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: MM4A Ref document number: E003952 Country of ref document: EE Effective date: 20110228 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20110202 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20110908 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110228 Ref country code: LT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110202 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110802 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110228 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110228 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: MM4A Ref document number: E 6838 Country of ref document: SK Effective date: 20110202 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20111102 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110902 Ref country code: LV Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110202 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110228 Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110202 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110203 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110202 Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110202 Ref country code: SI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110203 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110829 Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110901 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20100228 Year of fee payment: 4 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 502007001793 Country of ref document: DE Effective date: 20110901 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110228 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110202 |
|
RDAF | Communication despatched that patent is revoked |
Free format text: ORIGINAL CODE: EPIDOSNREV1 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110202 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20120411 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110203 |
|
RDAG | Patent revoked |
Free format text: ORIGINAL CODE: 0009271 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT REVOKED |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110202 |
|
27W | Patent revoked |
Effective date: 20120217 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MP4A Effective date: 20120627 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: LAPE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110202 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: ECNC |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 446100 Country of ref document: AT Kind code of ref document: T Effective date: 20120202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110203 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110901 Ref country code: BG Free format text: LAPSE BECAUSE OF REVOCATION BY EPO Effective date: 20110802 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120202 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: ECNC |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: ECNC |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: ECNC |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: ECNC |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110202 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: ECNC |